Omico.



40,000 REASONS TO ACT.

Building on 11 years of progress to make precision oncology part of everyday cancer care.

EXECUTIVE SUMMARY | 2026

40,000 REASONS TO ACT.

Building on 11 years of progress to make precision oncology part of everyday cancer care.

Precision oncology is changing what is possible for Australians facing cancer. The opportunity now is to make its benefits available to more people, faster, through routine cancer care.

Each year, at least **40,000 Australians with incurable solid cancers could potentially benefit from precision oncology.** This represents a substantial and continuing national need.

Over the past 11 years, **more than 40,000 Australians have been referred to Omico's research programs**, helping build the evidence, experience and national capability needed to make precision oncology work in Australia.

These two figures tell an important story: what has been achieved through research, and the continuing opportunity to bring precision oncology into routine cancer care for many more Australians.

Evidence of patient benefit

Omico's research has demonstrated how precision oncology can identify new treatment opportunities, connect patients with innovative therapies and extend lives.

71.3%

of patients profiled received a matched treatment recommendation[1]

19,316 PEOPLE

3,921

people accessed a clinical trial or matched therapy outside a trial[1]

~65%

longer median overall survival[2]

21.2 VS 12.8 MONTHS

BETH IVIMEY

Omico STAR Ambassador

(Screening and Therapy Advocate with Real-life Experience)

"You've got to live!"

"Every beat of my heart at my son's wedding was filled with love, joy and happiness. Thanks to Omico, I was there to share this unforgettable day with our family and friends. Without it, the day could have looked very different."




Australia has substantial national capability to build upon

Omico has built, operated and refined a National Research Engine for precision oncology — an interconnected system of infrastructure, technology, processes and specialist expertise that supports patients from referral through molecular profiling, expert interpretation, treatment and clinical trial matching, and follow-up.

Australia is not starting from scratch.

Omico's National Research Engine represents substantial capability and practical experience that Australia can draw upon to help integrate precision oncology into routine cancer care.



About Omico

Omico is helping transform what is possible for Australians affected by cancer — improving outcomes today while building the evidence for better cancer care tomorrow.

We are an independent, national, not-for-profit cancer research organisation that has worked for over 11 years to improve outcomes through research-led, evidence-based precision oncology.

*CaSP is a clinical research study approved by Monash Health Human Research Ethics Committee (RES-22-0000-537A).

Australia's next move: From research to routine care

Scientific progress is moving faster than Australia's ability to make advances in precision oncology available to patients.

Research programs have demonstrated what is possible but cannot meet the national need alone. A change to the health system is required.

Two challenges Australia must solve

1 Expand access to clinical trials and innovative treatments

Increase clinical trial capacity, improve equitable access to molecular profiling and strengthen the pathways connecting patients with treatment opportunities. This would also help attract international clinical research and investment to Australia.

2 Accelerate the implementation of effective innovations into routine care

Generate and evaluate evidence to inform better health policy, guide funding and implementation decisions, and ensure effective innovations reach more patients, faster. This will help direct healthcare resources where they deliver the greatest benefit.

These priorities must be addressed together, connecting earlier patient access with the evidence needed for broader implementation.

The solution: A nationally coordinated learning health system

Omico proposes establishing a new national institution — a **research-led learning health system (LHS)** — to connect clinical research, earlier patient access, real-world evidence generation and the implementation of effective innovations into routine care, dramatically shortening the time between scientific discovery and patient access.

A national LHS could:

- **Expand equitable patient access** and shorten the time to treatment with precision therapies by coordinating molecular profiling, clinical expertise and clinical trial opportunities across Australia.
- **Accelerate evidence generation** through clinical and real-world data.
- **Inform health policy, funding and implementation** decisions through evidence about effectiveness, value and health system impacts, supporting timely and sustainable adoption of beneficial innovations.
- **Strengthen clinical research and investment**, attracting new trials and partnerships to Australia.
- **Complement Australia's existing regulatory and health technology assessment processes**, generating evidence to support more timely, informed decisions.

Building on Australia's strengths

Australia already has substantial expertise, infrastructure, systems and evidence to draw upon. Omico's established national research capability and practical experience can make an important contribution.

The pieces exist. Now is the time to bring them together.

We have at least

40,000

REASONS TO ACT.

Every year.

References

1. Omico data from MoST + PrOSPeCT research cohorts.
2. Lin FP, Thavaneswaran S, Grady JP, *et al*. Genomic therapy matching in rare and refractory cancers. *JAMA Oncol*. Published online March 5, 2026. doi:10.1001/jamaoncol.2026.0127.

1800 954 350 | contact@omico.org.au | **omico.org.au**

© Copyright 2026. Australian Genomic Cancer Medicine Centre Ltd, trading as Omico, is a not-for-profit company limited by guarantee. Hilmer Building (E10), Union Rd, UNSW, Kensington, NSW, 2052

Omico.